AR113850A1 - Antagonistas de ildr2 y combinaciones de los mismos - Google Patents

Antagonistas de ildr2 y combinaciones de los mismos

Info

Publication number
AR113850A1
AR113850A1 ARP180103490A ARP180103490A AR113850A1 AR 113850 A1 AR113850 A1 AR 113850A1 AR P180103490 A ARP180103490 A AR P180103490A AR P180103490 A ARP180103490 A AR P180103490A AR 113850 A1 AR113850 A1 AR 113850A1
Authority
AR
Argentina
Prior art keywords
ildr2
seq
combinations
same
antagonists
Prior art date
Application number
ARP180103490A
Other languages
English (en)
Spanish (es)
Inventor
Ilan Vaknin
Ph D Levy Ofer Levy
John Hunter
D Pow Andrew Ph
Spencer Liang
Htter Julia Dr
Gritzan Uwe Dr
Rse Lars Dr
Original Assignee
Bayer Pharma AG
Bayer Ag
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag, Compugen Ltd filed Critical Bayer Pharma AG
Publication of AR113850A1 publication Critical patent/AR113850A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ARP180103490A 2017-11-30 2018-11-28 Antagonistas de ildr2 y combinaciones de los mismos AR113850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
AR113850A1 true AR113850A1 (es) 2020-06-17

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103490A AR113850A1 (es) 2017-11-30 2018-11-28 Antagonistas de ildr2 y combinaciones de los mismos

Country Status (16)

Country Link
US (1) US11655297B2 (enExample)
EP (1) EP3717007B1 (enExample)
JP (1) JP7350740B2 (enExample)
KR (1) KR20200096223A (enExample)
CN (1) CN111655287B (enExample)
AR (1) AR113850A1 (enExample)
AU (1) AU2018376231A1 (enExample)
BR (1) BR112020010767A2 (enExample)
CA (1) CA3083675A1 (enExample)
IL (1) IL274751B2 (enExample)
MX (1) MX2020005483A (enExample)
PE (1) PE20200956A1 (enExample)
RU (1) RU2020121533A (enExample)
SG (1) SG11202003323TA (enExample)
TW (1) TW201934119A (enExample)
WO (1) WO2019105972A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220169736A1 (en) * 2019-04-11 2022-06-02 Bayer Aktiengesellschaft Combinations of anti-ildr2 antibodies and pd-1 antagonists
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
LT2769729T (lt) 2007-09-04 2019-05-10 Compugen Ltd. Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
EP3202415B1 (en) * 2010-06-30 2021-12-08 Compugen Ltd. Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders.
WO2013001517A1 (en) * 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2756093A4 (en) * 2012-02-01 2015-07-01 Compugen Ltd C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
US20170233473A1 (en) * 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
SMT202500021T1 (it) 2014-04-10 2025-03-12 Daiichi Sankyo Co Ltd Metodo per produrre un coniugato anticorpo anti-her3-farmaco
WO2017049038A2 (en) 2015-09-16 2017-03-23 Ablexis, Llc Anti-cd115 antibodies

Also Published As

Publication number Publication date
JP7350740B2 (ja) 2023-09-26
RU2020121533A (ru) 2021-12-30
PE20200956A1 (es) 2020-09-24
CA3083675A1 (en) 2019-06-06
JP2021504404A (ja) 2021-02-15
SG11202003323TA (en) 2020-05-28
CN111655287A (zh) 2020-09-11
TW201934119A (zh) 2019-09-01
MX2020005483A (es) 2020-08-27
EP3717007C0 (en) 2025-09-17
AU2018376231A1 (en) 2020-05-07
EP3717007B1 (en) 2025-09-17
IL274751B2 (en) 2024-11-01
US20200369769A1 (en) 2020-11-26
WO2019105972A1 (en) 2019-06-06
IL274751A (en) 2020-07-30
BR112020010767A2 (pt) 2020-11-24
EP3717007A1 (en) 2020-10-07
KR20200096223A (ko) 2020-08-11
IL274751B1 (en) 2024-07-01
US11655297B2 (en) 2023-05-23
CN111655287B (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
AR113850A1 (es) Antagonistas de ildr2 y combinaciones de los mismos
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
DK3882275T5 (da) Bifunktionelt anti-pd-1- og anti-vegfa-antistof, farmaceutisk sammensætning deraf og anvendelse deraf
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
ZA202004907B (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
PL3476399T3 (pl) Przeciwciało lag-3, jego fragment wiążący i jego zastosowanie farmaceutyczne
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
EP3712170A4 (en) CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
CU24498B1 (es) Anticuerpos de factor xi
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
UY36194A (es) Anticuerpos anti-tau humanizados
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
CN106456764A8 (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
JOP20190096B1 (ar) مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي y
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
AR105267A1 (es) Anticuerpos de unión a tau
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
CO2017004753A2 (es) Anticuerpos que se unen a ccr6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal